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Abstract
Background: The objective of this study was to evaluate the safety of total thyroidectomy for thyroid disorders and
summarise the treatment experience in a less-developed region.
Methods: This was a retrospective observational cohort study using the computerised database of the First Affiliated
Hospital of Harbin Medical University. All consecutive thyroidectomy patients from 2003 to 2014 were included in this
study. Demographics, surgical procedure, diagnoses, morbidity and mortality were retrospectively reviewed.
Results: There were a total of 714 men and 4845 women in this study, with a mean age of 55 (range 9–87) years.
A total of 4632 patients underwent total thyroidectomy for primary surgical treatment, and 189 patients previously
underwent partial thyroidectomy. A total of 56.2 % of the patients had multinodular goitre, including 12.23 % who were
thyrotoxic. Graves’ disease and Hashimoto’s disease were diagnosed in 2.82 and 7.23 % of the patients, respectively.
Papillary thyroid cancer was identified in 1336 patients, 44.99 % of whom had papillary microcarcinoma. The total
prevalence of permanent complications of first-time and secondary surgeries was 0.35 and 7.41 %, respectively. During
thyroid surgery, 945 patients underwent parathyroid autotransplantation.
Conclusions: Initial total thyroidectomy can be safely performed for both benign and malignant thyroid diseases in a
less-developed region. The morbidity of a secondary surgical procedure after subtotal thyroidectomy is significantly high
compared to first-time surgery.
Keywords: Total thyroidectomy, Subtotal thyroidectomy, Papillary thyroid carcinoma, Thyroid surgery,
Hypoparathyroidism, Recurrent laryngeal nerve injury
Background
In recent years, the incidence of thyroid disorders, includ-
ing thyroid malignancy, has increased rapidly; however, the
reasons why the incidence of thyroid diseases is increasing
substantially are not yet completely understood. Routine
physical check-ups, particularly the widespread application
of high-resolution ultrasonography, may explain this trend
[1]. Moreover, iodine deficiency diseases (IDDs) are wide-
spread in China, and Heilongjiang province is one of the
IDD-endemic areas. After the nationwide introduction of a
mandatory universal salt iodisation (USI) programme in
1996, IDDs may have been effectively controlled [2]. Be-
cause of the higher iodine concentration in edible salt in
our country than the WHO-recommended standard and
because of the local eating habits, a high-salt diet may lead
to excessive iodine intake. However, the excessive iodine in-
take problems caused by the Chinese USI programme have
not yet been taken seriously [3] and may account for the in-
creasing incidence of thyroid diseases [3, 4]. Total thyroid-
ectomy (TT) is undoubtedly the optimal surgical treatment
for high-risk thyroid cancer; however, the rationality of this
surgical approach for the treatment of benign multinodular
goitre, toxic multinodular goitre and Graves’ disease and
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even for the treatment of low-risk well-differentiated
thyroid carcinomas remains controversial [5–9]. The
disequilibrium of medical resources makes increasing
numbers of patients from less-developed areas become
concentrated in a large hospital such as ours. For patients
here, the cost to cure their disorders ranges from a month
or even a year’s income, and many patients do not return
for regular re-examination because of economic factors.
The objective of this study was to determine whether TT
is an effective, safe and appropriate procedure to manage
thyroid diseases and provide insight into the management
of thyroid diseases in economically less-developed areas.
Methods
A retrospective review was conducted to all patients
undergoing thyroid surgery between 2003 and 2014 at the
First Affiliated Hospital of Harbin Medical University. All
clinical and pathological data were entered prospectively
into a computerised database. We extracted data on the
sex, age, nature of thyroid disease, incidence of postopera-
tive complications and final pathology from the depart-
mental medical records. The Medical Ethics Committee at
First Affiliated Hospital of Harbin Medical University
(Harbin, Heilongjiang, China) approved this study, and all
patients signed informed consents.
Preoperative evaluation
Preoperative evaluation in all patients included serum
thyroid hormones, thyroid antibodies, parathyroid hor-
mone (PTH), calcium, indirect laryngoscopy and neck
ultrasonography. For patients with thyroid nodules, fine
needle aspiration is the most appropriate examination to
provide a rapid and accurate assessment. Very aggressive
cancers, such as poorly differentiated and anaplastic thy-
roid cancers, which may invade local structures, require
deliberate planning. Computed tomography (CT) is also
performed in all patients to provide important adjunct
anatomical information about the thyroid as well as
related structures in the neck, and it is a necessary pre-
operative imaging study that affects both the extent of
surgery and method of anaesthesia induction [10–12].
All thyrotoxic patients received pharmacologic therapy
preoperatively, such as beta-blockers, which were con-
tinued until 10–14 days after the surgery to prevent
perioperative thyroid crisis. TT was performed for pa-
tients with thyroid nodules involving both lobes, Graves’
disease and toxic goitre in our institution.
Surgical procedure
After the induction of anaesthesia, the neck is gently
extended with a cushion under the shoulders. Surgery
begins with the design of incisions, which should bal-
ance incision aesthetics and adequate exposure for safe
surgery. A collar incision two fingerbreadths above the
clavicle within or parallel to the skin line will not only
assure a minimal incision scar but also provide sufficient
exposure. Routine local anaesthesia was used to facilitate
a free skin flap and alleviate pain postoperatively. The
anterior cervical muscle group was routinely divided
lengthways, and the thyroid gland was dissected on the
plane of the capsule, with careful ligation of all vessels.
Both recurrent laryngeal nerves (RLNs) were exposed
routinely during the course of the dissection, and intra-
operative electrophysiological nerve integrity monitoring
was not used in our procedures. Every attempt was
made to identify and preserve the parathyroid glands in
situ. Parathyroid glands that could not be preserved with
an adequate blood supply were meticulously dissected
from the thyroid gland, diced and autotransplanted in
the sternocleidomastoid muscle at the end of the oper-
ation. This technique is widely practiced and is an effi-
cient method of avoiding long-term hypoparathyroidism.
No drainage tube or suction drainage with negative pres-
sure was needed when only hemithyroidectomy (HT) or
TT with/without central neck dissection was completed.
When lateral neck dissection was performed, a drainage
tube was required in case of lymphatic or chylous leak.
Postoperative management and postoperative follow-up
Lifelong treatment of levothyroxine replacement was
required at a dose of 100–200 μg per day, depending on
weight and sex, and serum TSH was followed up to
adjust the dose of levothyroxine. Routine 2-week oral
calcium and vitamin D supplementation (Caltrate D,
Wyeth, USA, containing 1.5 g calcium carbonate and
vitamin D3 125 IU in each tablet) without laboratory
assessment was administered to all patients who had
total thyroidectomy, and this method is a safe and cost-
effective for preventing symptomatic hypocalcaemia
[13, 14]. Patients take 3 g of calcium three times daily
for the first week and 1.5 g three times daily for the
second week. If symptoms of hypocalcaemia remain,
additional doses of 2 g of calcium gluconate are intra-
venously injected. Hypoparathyroidism was considered
permanent if a calcium supplement was still required
after 6 months. In patients with hoarseness, an add-
itional indirect laryngoscopy was scheduled at 1, 3 and
6 months after surgery or until the vocal cord function
recovered. After 6 months, we considered RLN palsy to
be permanent. Based on the patient’s physical condition
and will, patients of TT, HT and TT + CND were usu-
ally discharged within 2–3 days after surgery. Patients
who underwent modified neck section were not
discharged until the drainage tube was removed, which
occurred when the drainage fluid was less than 25 ml
for three consecutive days. Patients with Horner’s
syndrome, chylous leakage, severe dyspnoea causing
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tracheomalacia or RLN palsy and haemorrhage had
delayed discharge.
Results
A total of 5559 thyroid operations were performed
between 2003 and 2014. There were 714 men and 4845
women with a mean age of 52 (range 9–87) years. The
basic characteristics of the patients and the stage of pa-
tients with malignant diseases are presented in Table 1.
All patients underwent thyroidectomy, as a first-time
surgery in 5370 patients and as a secondary thyroid sur-
gery in 189 patients. Of the reoperations, 138 previously
underwent subtotal thyroidectomy (ST) for multinodular
goitre and required a complete thyroidectomy for recur-
rent diseases. In addition to the thyroid surgery, 217 pa-
tients had central neck dissection and 108 had modified
neck dissection. HT was performed initially for 413 pa-
tients with a solitary nodule or multiple lesions within
one lobe, and all removed tissue was revealed as benign
by intraoperative frozen pathological section. A total of
51 patients required a HT for recurrent disease (Table 2).
A total of 945 patients underwent parathyroid autotrans-
plantation, and none suffered from permanent hypo-
parathyroidism. Of the 945 patients, 1302 parathyroid
glands were autotransplanted and 102 were intrathyroi-
dal parathyroid.
Table 3 summarises the postoperative histopatho-
logical diagnosis based on paraffin section examination
of the resected thyroid glands. Of these, 56.2 % of the
patients had multinodular goitre, including 12.23 % who
were thyrotoxic. Graves’ disease and Hashimoto’s disease
were diagnosed in 2.82 and 7.23 % of the patients,
respectively. Papillary thyroid cancer was identified in
1336 patients, 44.99 % of whom had papillary
microcarcinoma.
Table 2 also shows the complications of the various
thyroid operations, and the incidence of postoperative
complications was compared between patients with dif-
ferent approaches. There was no mortality in the post-
operative period. Haemorrhage, a serious complication
requiring reoperation, only occurred in a 38-year-old
female patient who underwent TT with modified neck
dissection. For the first-time surgery, permanent RLN
injury occurred in 18 patients, including three cases of
nonrecurrent laryngeal nerve and 9 cases of tumour in-
vasion. Furthermore, during secondary completion thy-
roidectomy after ST, we could not successfully expose
the RLN in 34 patients as a consequence of fibroblasts
and scar tissue. Of these, 10 had unilateral permanent
RLN palsy and 1 patient had bilateral permanent RLN
palsy. The incidence of permanent RLN injury combined
with permanent hypoparathyroidism for the first-time
surgery was 0.35 %, and the permanent complication
rate of the secondary surgery was 7.41 %, including both
completion thyroidectomy after ST and LT (lobectomy)
after HT. Moreover, the relationship between the grade
of goitre and the complication rates of initial TT is
shown in Table 4. The grading system is as follows: a
goitre that can be touched but cannot be seen is grade I;
a goitre that can be both touched and seen but is not be-
yond the exterior margin of the sternocleidomastoid
muscle is grade II; and a goitre that can be both touched
and seen and is beyond the exterior margin of sterno-
cleidomastoid muscle is grade III.
A total of 33 patients with solitary nodule or lesions
with one lobe based on the US diagnosis were found to
have micropapillary cancer in the contralateral lobe
postoperatively.
Discussion
The availability of levothyroxine replacement therapy
makes patients who underwent TT, an iatrogenic thyroid
absence, survive with euthyroid function, such that TT
is a feasible management strategy for thyroid diseases.
There is an increase in the utilisation of TT worldwide
for the management of thyroid diseases [9, 15–18],
although controversy remains for benign thyroid disor-
ders and low-risk thyroid cancers. However, the signifi-
cant role of this procedure is clear. Because thyroid
diseases are rapidly increasing, we have attempted to es-
tablish an appropriate practice for thyroid disorders in
Table 1 Characteristics of 5559 patients and stages of
malignant thyroid cancer
Sex ratio (M/F) 714:4845








With thyroid nodule(s) 497
Hypothyroid with thyroid nodules 601
Stage of malignant thyroid cancera
Total malignant thyroid disease 1640
Patient older than 45 years 1295 (78.96 %)
I 844 (51.46 %)
II 411 (25.06 %)
III 264 (16.10 %)
IV 121 (7.38 %)
aStaging according to the seventh edition of AJCC Cancer Staging
Manual 2010
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economically underdeveloped areas, and the establish-
ment of these practices is based on concepts, principles,
practical experience and patient preference.
Total thyroidectomy versus thyroid lobectomy for
low-risk papillary thyroid carcinoma
Surgery is the basic treatment for thyroid malignancy,
but for low-risk papillary thyroid cancer, there has been
a long unsolved debate about the extent of primary sur-
gery [6]. Papillary thyroid cancer covers the majority of
thyroid cancers and has a favourable long-term survival
rate [19–21]. The 10-year relative survival rate for
patients with papillary thyroid cancer was 93 % for those
treated in the USA [22]. The excellent disease-specific
survival rates of low-risk thyroid cancer and the possible
surgical complications associated with a more extensive
approach make HT a preferred treatment for patients
with a solitary nodule or lesions within one lobe accord-
ing to some experts. The controversy focuses on the fol-
lowing points: (a) Does the bilateral procedure promote
the overall survival rates? (b) Is the recurrence rate de-
creased by a more extensive surgery? (c) Compared to
HT, is there an increase of complication rates associated
with TT? (d) Can removing all thyroid tissue provide an
adjuvant therapy and/or less complicated monitoring for
recurrence disease? (e) Can the cost-effectiveness and
quality of life be improved with a thorough surgical
procedure?
In some retrospective studies, the mortality rates for
low-risk well-differentiated thyroid cancer were extremely
low, even during a relatively long follow-up period regard-
less of the extent of the initial surgery [23–25]. However,
because of the absence of randomised prospective trials
and a long enough follow-up time, it remains unclear
whether there is a significant difference in the survival
rates between HT and TT performed for patients with
low-risk thyroid carcinoma. The disease recurrence rates
are lower with TT in most studies [20, 23, 26, 27].
Although the recurrent diseases may be excised without
increasing the complications and without affecting sur-
vival, an extra medical cost is incurred, including medical
examination and reoperation, and the psychological bur-
den of the fear of progression of malignant disease is not
assessable as a pecuniary loss. Biological characteristics of
papillary cancer are bilateral and multifocal [28, 29], and
this matches our experience. In view of such an under-
standing, TT can remove all foci to the maximum extent.
Complications associated with thyroid surgery are cer-
tainly a treatment consideration. Choosing HT for primary
surgical treatment may be associated with lower complica-
tion rates [30, 31]; however, considering the trend towards
lower morbidity when performed by experienced surgeons
and the high risk of complication rates of completion
Table 2 Complications of the various thyroid operations
First-time surgery (n = 5370) Revision surgery (n = 189)
Complication TT (4632) HT (413) TT + CND (217) TT + MND (108) Total CT after ST (138) LT after HT (51) Total
RLN injury no. (%)
Temporary 29 (0.63) 4 (0.10) 8 (3.69) 4 (3.70) 45 (0.84) 19 (13.77) 2 (3.92) 21 (11.11)
Permanent 15 (0.32) 0 (0) 2 (0.92) 1 (0.93) 18 (0.34) 11 (7.97) 0 (0) 11 (5.82)
Total 44 4 10 5 63 30 2 32
Hypoparathyroidism no. (%)
Temporary 152 (3.28) 9 (2.18) 19 (8.76) 10 (9.26) 190 (3.53) 25 (18.12) 1 (1.96) 26 (13.76)
Permanent 1 (0.02) 0 (0) 0 1 (0.02) 1 (0.02) 3 (2.17) 0 (0) 3 (1.59)
Total 153 9 19 191 191 28 1 29
TT total thyroidectomy, HT hemithyroidectomy, CND central neck dissection, MND modified neck dissection, CT completion thyroidectomy, LT lobectomy, ST
subtotal thyroidectomy, RLN recurrent laryngeal nerve




Multinodular goitre 3124 56.20
Toxic 382 6.87
Non-toxic 2766 49.76
Graves’ disease 157 2.82
Hashimoto’s disease 402 7.23
Subacute thyroiditis 85 1.53
Follicular adenoma 107 1.92
Malignant 1640 29.50
Papillary thyroid carcinoma 1336 24.03
Microcarcinoma 601 10.81
With Hashimoto’s disease 297 5.34
With Graves’ disease 43 0.77
Follicular carcinoma 130 2.34
Medullary carcinoma 65 1.17
Anaplastic carcinoma 4 0.07
Other 104 1.87
Total 5559 100
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thyroidectomy for recurrent diseases, the bilateral proced-
ure as an initial treatment is a wise choice. Furthermore,
TT will facilitate radioactive iodine ablation treatment for
adjuvant therapy and serum thymoglobulin (Tg) level
monitoring for disease recurrence. For the initial surgical
treatment, TT dominates over HT as the most cost-
effective surgical management for low-risk thyroid carcin-
oma, and this approach maximises the quality-adjusted life
expectancy in patient PTC compared to lobectomy [32].
Total thyroidectomy versus subtotal thyroidectomy for
benign thyroid diseases
TT is controversial for low-risk malignant diseases and
benign thyroid diseases. Compared with ST, in recent
years, TT is increasingly utilised as the first-time surgical
treatment for benign bilateral thyroid diseases, including
Graves’ disease and toxic and non-toxic multinodular
goitres [7, 9, 15–17]. However, understanding and apply-
ing this approach remains difficult in our locality, and
bilateral subtotal thyroidectomy (BST) was the principal
procedure for bilateral benign thyroid disease until now.
Compared to ST, the extent of TT involves two ex-
tremely critical and vulnerable structures, the RLN and
the parathyroid, and the related complications are the
major deterrent to surgeons performing this approach.
For ST, leaving a small portion of thyroid tissue in situa-
tions where it protects RLNs and the parathyroid from
the injury of extensive manipulation seems to reduce
morbidity rates compared to TT. In fact, the incidence
of permanent morbidity after initial TT is reportedly
low and is comparable to ST [9, 33]. Currently, it is
unequivocally acknowledged that the routine exposure
of RLN significantly reduces the risk of RLN injury
[24, 34]. Furthermore, parathyroid autotransplantation
is widely used and avoids the risk of permanent hypopara-
thyroidism [35, 36]. Additionally, remnant thyroid tissues,
following ST for multinodular goitre, have a high percent-
age of micronodule formation with remarkable cellular
proliferative activity [37, 38]. The recurrence rates of bilat-
eral multinodular goitre after ST are significantly higher
than for those who underwent TT, and the recurrence
rates remain high even with treatment of levothyroxine
suppression, which was once advocated to control the
progression of benign thyroid nodules and prevent recur-
rence after partial thyroid surgery [9, 39, 40]. Thyroid sur-
gery provides an effective and immediate solution for
Graves’ disease, and it improves the quality of life for pa-
tients [41]. Compared to ST, TT is associated with a re-
duced incidence of recurrent hyperthyroidism and should
be proposed for the treatment for Graves’ disease [8, 42].
In our surgical experience of first-time thyroidectomy, 879
patients had intraoperatively nonpalpable lesions (101 ma-
lignant and 778 benign) nearby the berry ligament, which
remains when ST is performed instead of TT. As a conse-
quence, removing all thyroid tissue for the first time es-
sentially eliminates the risk of developing recurrent
disease and thyroid carcinoma in the remnant tissue with-
out an accompanying increased risk of permanent hypo-
parathyroidism or RLN injury.
The association of Hashimoto’s thyroiditis and thyroid
cancer warrants a thorough examination for patients
with thyroid nodules [43–45]. Therefore, we propose
that TT should be performed for patients with thyroid
nodules and this hypothesis should be tested by clinical
controlled trials.
The avoidance of permanent hypoparathyroidism and
bilateral RLN palsy is of prime importance, and the
complications from these may be detrimental to the
physical and mental health of the patient rather than the
thyroid diseases themselves. During the identification
and protection of the RLN and parathyroid intraopera-
tively, there is an increase in the temporary complication
rates occurring in patients with giant thyroid goitre and
Graves’ disease in our experience of first-time surgery.
Our preliminary analysis suggests that gland goitre
compression and inflammatory conglutination make it
Table 4 Relationship between grade of goitre and complication rates of initial TT
Grade of goitre (n = 4632)
Complication 0 (n = 1302) I (n = 2063) II (n = 828) III (n = 439)
RLN injury
Temporary 2 (0.15 %) 6 (0.29 %) 3 (0.36 %) 18 (4.1 %)
Permanent 4 (0.31 %) 7 (0.34 %) 3 (0.36 %) 1 (0.22 %)
Total 6 9 10 19
Hypoparathyroidism
Temporary 18 (1.38 %) 30 (1.45 %) 33 (4.00 %) 71 (16.17 %)
Permanent 0 (0) 0 (0) 1 (0.12 %) 0 (0)
Total 18 30 34 71
RLN recurrent laryngeal nerve, 0 goitre that cannot be touched or seen, I goitre that can be touched but cannot be seen, II goitre that can be both touched and
seen but is not beyond the exterior margin of the sternocleidomastoid muscle, III goitre that can be both touched and seen but is beyond the exterior margin of
the sternocleidomastoid muscle
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difficult to separate and reserve the RLN and parathy-
roid smoothly without any further stretching. Neverthe-
less, because there is no increase in the risk of
permanent complications, we propose that such a transi-
ent injury of the RLN and parathyroid is controllable,
and in our opinion, although this practice is difficult, the
RLN and parathyroid can be preserved. However, main-
taining the RLN and parathyroid during the revision sur-
gery after ST is a different situation. Because of scar
tissue and adhesion formation, the normal anatomical
form, position and space of the adjacent tissue are ob-
scured and injury of the RLN and parathyroid usually
occurs without any warning intraoperatively. Therefore,
no matter how meticulously the surgery was performed,
even by experienced surgeons, the incidence of perman-
ent RLN palsy and hypoparathyroidism of secondary
surgery remains at a high level. The same result was re-
ported in many studies [46–48]. Revision surgery for
BST patients will not only increase the risk to patients
but also increase the psychological pressure for the sur-
geons performing the procedures. In conclusion, a thor-
ough initial surgical treatment should be adopted to
avoid any potential and additional risks of reoperative
surgery for recurrent diseases, and we suggest ‘one side,
once operation’, which recommends that if lesion is
within one lobe, then total lobectomy should be per-
formed, and if the thyroid disorder is diffuse or involves
two sides, total thyroidectomy should be performed. Re-
peat thyroid surgery for recurrent goitre after hemithyr-
oidectomy for unilateral lesion does not carry an
increased risk if the contralateral side has been left
untouched.
Patient preferences
Evidence-based medicine integrates the patient prefer-
ences with clinical experience and the best research evi-
dence to make optimal medical decisions. Thus, when
the patient is well informed of all implications and on
the prerequisite of not violating the principle medical
care, the patient’s wishes should be fully respected.
Generally, patient preferences depend on the following
factors for the treatment of thyroid diseases: (a) cancer-
isation; (b) recurrence; (c) cost, including examination,
surgery, medical therapy and re-examination; (d) psy-
chological burden; (e) lifelong levothyroxine replace-
ment; (f ) tolerance of medical therapies and associated
side effects, such as anti-thyroid gland medicine; (g)
education level; (h) income; and (i) medical insurance.
Local patients who were subject to economic factors
prefer a procedure that cures the diseases once and for
all because such a solution may minimise the cost of
postoperative management and examination and sur-
gery for recurrent disease. Furthermore, compared to
lifelong replacement therapy, repetitive examination
because of the fear of recurrent disease will not only in-
crease the cost but also aggravate the psychological
burden. As an immediate and permanent cure, TT is a
more worthwhile and necessary approach for most pa-
tients in our locality. Therefore, in an economically
less-developed region, TT coincides better with patient
preferences, at least in our experience.
A major drawback of this study is the lack of a thor-
ough long-term follow-up; therefore, we cannot discuss
the issue with data for the long-time survival rate of
malignant thyroid diseases (particularly low-risk thyroid
cancer) and recurrent disease. Another limitation is that
all surgeries were performed or were under the supervi-
sion of the same experienced surgeon (Linfeng Wu), and
this may cause a subjective preference and personal limi-
tation for management for thyroid diseases, although
our clinical decisions were based on evidence-based
medicine. Furthermore, the small sample size of the
secondary surgery group compared to the first-time sur-
gery group must be considered.
Conclusions
TT is an effective and safe approach based on increasing
evidence. To prevent the hard-to-reduce prevalence of
permanent complications of repeat surgery for recurrent
disease, we prefer TT as an initial treatment for Graves’
disease and multinodular goitre when both lobes are in-
volved. Because of the significantly lower rate of recur-
rence and no need for secondary surgery after malignant
disease is confirmed by FNA or intraoperative frozen
section, TT is performed whether the contralateral lobe
is involved. Furthermore, the core principle of all surgi-
cal management of thyroid diseases is ‘one side once op-
eration,’ and this principle should be widely disseminated
to deepen the understanding that the true essence of
thyroidectomy is the safety of the RLN and parathyroid
gland. Therefore, in response to the rapid increase of
thyroid diseases in less-developed regions, TT may be
considered the most reasonable treatment of choice for
patients with thyroid disorders.
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